Scholar Rock Holding Corporation SRRK
48.27 USD -3.28 (-6.37%)
Nov 10, 2026, 3:01 PM EST
47.33 Day range 52.03
28.97 52-week range 61.76
- YTD
- +9.57%
- 1 year
- +64.33%
News
marketbeat.com What Scholar Rock (SRRK) Said on Its Q3 Earnings Call Scholar Rock NASDAQ: SRRK reported $0.6 million in third-quarter revenue from initial shipments of its newly approved spinal muscular atrophy treatment ISEMBYLD, while executives said insurance and…
seekingalpha.com Scholar Rock Holding Corporation (SRRK) Q3 2026 Earnings Call Transcript Scholar Rock Holding Corporation (SRRK) Q3 2026 Earnings Call Transcript
benzinga.com Scholar Rock Holding Q3 2026 Earnings Call Transcript Scholar Rock Holding (NASDAQ:SRRK) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
zacks.com Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Beats Revenue Estimates Scholar Rock Holding Corporation (SRRK) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $0.9 per share a year ago.
benzinga.com BioNTech To Acquire FDA Priority Review Voucher From Scholar Rock For $205M In Cash A PRV grants FDA priority review for a single application, which reduces the target FDA review timeline and could lead to expedited approval. BioNTech intends to use the PRV to support a future…
benzinga.com Scholar Rock Holding Q3 EPS $(0.81) Beats $(0.85) Estimate, Sales $600.000K Beat $22.429K Estimate Scholar Rock Holding (NASDAQ:SRRK) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.85) by 4.71 percent. This is a 10 percent increase over losses of…
benzinga.com Petrobras, TransDigm On Deck Tuesday As Oil Profits, Aerospace Demand Face Test Petroleo Brasileiro headlines Tuesday’s reports, with investors weighing whether strong production and operating performance can offset pressure on energy prices. TransDigm Group, Honda Motor, Sea,…
benzinga.com Scholar Rock Refiles Marketing Authorisation Application With EMA For Apitegromab To Treat Children And Adults With Spinal Muscular Atrophy Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading…
benzinga.com Scholar Rock Holding Reports Q2 2026 Results: Full Earnings Call Transcript Scholar Rock Holding (NASDAQ:SRRK) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga…- benzinga.com Truist Securities Maintains Buy on Scholar Rock Holding, Raises Price Target to $77 Truist Securities analyst Srikripa Devarakonda maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $76 to $77.
benzinga.com JP Morgan Maintains Overweight on Scholar Rock Holding, Raises Price Target to $70 JP Morgan analyst Tessa Romero maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $63 to $70.
benzinga.com Evercore ISI Group Maintains Outperform on Scholar Rock Holding, Raises Price Target to $72 Evercore ISI Group analyst Cory Kasimov maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and raises the price target from $65 to $72.
benzinga.com Piper Sandler Maintains Overweight on Scholar Rock Holding, Raises Price Target to $75 Piper Sandler analyst Allison Bratzel maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $60 to $75.- benzinga.com Jefferies Maintains Buy on Scholar Rock Holding, Raises Price Target to $65 Jefferies analyst Amy Li maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $57 to $65.
benzinga.com This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Analysts downgraded Banco Santander Brasil, Ribbon Communications, Cellectis, Scholar Rock, with mixed price-target changes.- benzinga.com Wedbush Maintains Outperform on Scholar Rock Holding, Raises Price Target to $70 Wedbush analyst David Nierengarten maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and raises the price target from $64 to $70.
benzinga.com Zebra Technologies To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday Analysts cut Exodus’ target, raised targets for Teledyne, Roblox, Scholar Rock, Zebra, Agilon, SM Energy and Paymentus; Agilon upgraded to Outperform.
benzinga.com Barclays Downgrades Scholar Rock Holding to Equal-Weight, Raises Price Target to $58 Barclays analyst Etzer Darout downgrades Scholar Rock Holding (NASDAQ:SRRK) from Overweight to Equal-Weight and raises the price target from $55 to $58.- benzinga.com HC Wainwright & Co. Maintains Buy on Scholar Rock Holding, Raises Price Target to $70 HC Wainwright & Co. analyst Andres Y. Maldonado maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $65 to $70.
- benzinga.com Raymond James Maintains Strong Buy on Scholar Rock Holding, Raises Price Target to $72 Raymond James analyst Gary Nachman maintains Scholar Rock Holding (NASDAQ:SRRK) with a Strong Buy and raises the price target from $65 to $72.
- benzinga.com BMO Capital Maintains Outperform on Scholar Rock Holding, Raises Price Target to $84 BMO Capital analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and raises the price target from $76 to $84.
- benzinga.com Truist Securities Reiterates Buy on Scholar Rock Holding, Raises Price Target to $76 Truist Securities analyst Srikripa Devarakonda reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $55 to $76.
benzinga.com Citigroup Maintains Buy on Scholar Rock Holding, Raises Price Target to $74 Citigroup analyst Geoff Meacham maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $60 to $74.
benzinga.com Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy FDA approves Scholar Rock Isembyld to treat spinal muscular atrophy in adults and pediatric patients two years and older.- benzinga.com Wedbush Reiterates Outperform on Scholar Rock Holding, Maintains $64 Price Target Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and maintains $64 price target.
benzinga.com Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premarket gainers, while Picocela fell.- benzinga.com HC Wainwright & Co. Reiterates Buy on Scholar Rock Holding, Maintains $65 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $65 price target.
- benzinga.com Scholar Rock Receives FDA's Fast Track And Orphan Drug Designations For Apitegromab To Treat Facioscapulohumeral Muscular Dystrophy Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading…
benzinga.com Scholar Rock Removes Catalent Indiana As Commercial Fill-Finish Facility From Its Apitegromab BLA For The Treatment Of Spinal Muscular Atrophy Under Guidance From The FDA; Now On Track To Submit Apitegromab Japanese New Drug Application By End-2026 FDA review of BLA progressing well with Scholar Rock’s alternate fill-finish facilityCompany is prepared for U.S. apitegromab launch immediately upon FDA approval, which may be granted at any time…- benzinga.com JP Morgan Maintains Overweight on Scholar Rock Holding, Raises Price Target to $63 JP Morgan analyst Tessa Romero maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $56 to $63.
benzinga.com Scholar Rock Overcomes Manufacturing Hurdle to Keep Lead Drug FDA Review on Schedule Scholar Rock shifts its FDA review for SMA treatment apitegromab to a secondary facility, keeping the September 30 approval date on schedule.- benzinga.com Wedbush Reiterates Outperform on Scholar Rock Holding, Maintains $58 Price Target Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and maintains $58 price target.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Scholar Rock Holding, Maintains $65 Price Target HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $65 price target.
- benzinga.com Citigroup Maintains Buy on Scholar Rock Holding, Raises Price Target to $60 Citigroup analyst Geoff Meacham maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $58 to $60.
- benzinga.com Scholar Rock Removes Catalent Indiana From Apitegromab BLA After FDA OAI Classification; FDA Review Remains On Track for Sept. 30 PDUFA Using Second Fill-Finish Site Today, August 7, 2026, Scholar Rock received customer notification from Catalent Indiana LLC (part of Novo Nordisk) that FDA classified the April 2026 site inspection of Catalent Indiana fill-finish…
- benzinga.com Scholar Rock Holding Q2 EPS $(0.84) Beats $(0.85) Estimate; Cash Balance Of $492M Scholar Rock Holding (NASDAQ:SRRK) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(0.85) by 1.18 percent. This is a 14.29 percent increase over losses of…
- benzinga.com Wedbush Reiterates Outperform on Scholar Rock Holding, Maintains $58 Price Target Wedbush analyst David Nierengarten reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and maintains $58 price target.
- benzinga.com Scholar Rock Announces European Medicines Agency Reviewing Apitegromab Marketing Authorisation Application To Treat Spinal Muscular Atrophy; Committee For Medicinal Products For Human Use Anticipated Later This Year If FDA Reclassifies Catalent Indiana Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading…
- benzinga.com Barclays Maintains Overweight on Scholar Rock Holding, Raises Price Target to $55 Barclays analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $53 to $55.
- benzinga.com HC Wainwright & Co. Maintains Buy on Scholar Rock Holding, Raises Price Target to $65 HC Wainwright & Co. analyst Andres Y. Maldonado maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $58 to $65.
- benzinga.com Canaccord Genuity Initiates Coverage On Scholar Rock Holding with Buy Rating, Announces Price Target of $62 Canaccord Genuity analyst Gary Nachman initiates coverage on Scholar Rock Holding (NASDAQ:SRRK) with a Buy rating and announces Price Target of $62.
benzinga.com Scholar Rock To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday Top Wall Street analysts changed their outlook on top names. For a complete view of all rating changes, see analyst ratings page.- benzinga.com Wedbush Maintains Outperform on Scholar Rock Holding, Raises Price Target to $58 Wedbush analyst David Nierengarten maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and raises the price target from $56 to $58.
benzinga.com Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave…
benzinga.com Scholar Rock Resubmits FDA Biologics License Application For Apitegromab For Spinal Muscular Atrophy, PDUFA Action Date Expected In Late September 2026 Apitegromab BLA resubmission includes Catalent Indiana LLC (part of Novo Nordisk) and second U.S.-based fill-finish facility, aligned with FDA guidance from March 3, 2026 Type C meetingFDA and Novo…- benzinga.com JP Morgan Maintains Overweight on Scholar Rock Holding, Raises Price Target to $50 JP Morgan analyst Tessa Romero maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $47 to $50.
- benzinga.com Citigroup Maintains Buy on Scholar Rock Holding, Raises Price Target to $58 Citigroup analyst Geoff Meacham maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $55 to $58.
- benzinga.com BMO Capital Maintains Outperform on Scholar Rock Holding, Raises Price Target to $70 BMO Capital analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Outperform and raises the price target from $50 to $70.
- benzinga.com Truist Securities Maintains Buy on Scholar Rock Holding, Raises Price Target to $55 Truist Securities analyst Srikripa Devarakonda maintains Scholar Rock Holding (NASDAQ:SRRK) with a Buy and raises the price target from $44 to $55.
- benzinga.com Barclays Maintains Overweight on Scholar Rock Holding, Raises Price Target to $53 Barclays analyst Etzer Darout maintains Scholar Rock Holding (NASDAQ:SRRK) with a Overweight and raises the price target from $52 to $53.